Core Insights - Xilio Therapeutics, Inc. is set to present multiple clinical and preclinical data at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting from November 6-9, 2025, focusing on tumor-activated immuno-oncology therapies for cancer patients [1][2]. Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing tumor-activated immuno-oncology therapies aimed at improving patient outcomes while minimizing systemic side effects associated with current treatments [2]. Upcoming Presentations - The company will present clinical data for vilastobart, an anti-CTLA-4 therapy, and efarindodekin alfa (XTX301), an IL-12 therapy, along with preclinical data on masked T cell engager programs [2]. - Specific poster presentations include: - "ctDNA as a Potential Surrogate Biomarker for Response to Combination Vilastobart and Atezolizumab in Heavily Pretreated Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)" on November 7, 2025 [4]. - "XTX301, a Tumor-Activated Interleukin-12 (IL-12), Demonstrated IL-12 Pharmacology in Patients with Advanced Solid Tumors: Pharmacodynamic Data from First-in-Human Phase 1 Study" on November 7, 2025 [4]. - "Masked T Cell Engagers Designed to Drive Potent Synthetic Anti-Tumor Immunity with Favorable Tolerability" on November 8, 2025 [4].